
Brenda Libby Coleman
Examiner (ID: 13884, Phone: (571)272-0665 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1202, 2611, 1624, 1611 |
| Total Applications | 3154 |
| Issued Applications | 1967 |
| Pending Applications | 488 |
| Abandoned Applications | 741 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18297346
[patent_doc_number] => 20230107032
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
[patent_app_type] => utility
[patent_app_number] => 17/850144
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 92481
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850144
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850144 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | Jun 26, 2022 | Issued |
Array
(
[id] => 18109509
[patent_doc_number] => 20230002389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/836070
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9235
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 254
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836070
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836070 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | Jun 8, 2022 | Pending |
Array
(
[id] => 18179980
[patent_doc_number] => 20230040709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => TRIDENTATE MACROCYCLIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/833160
[patent_app_country] => US
[patent_app_date] => 2022-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12678
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17833160
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/833160 | Tridentate macrocyclic compounds | Jun 5, 2022 | Issued |
Array
(
[id] => 18211579
[patent_doc_number] => 20230057842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => ALBOFUNGIN AND ITS DERIVATIVES SPECIFICALLY RECOGNIZE HIV-1 LTR-III G-QUADRUPLEX
[patent_app_type] => utility
[patent_app_number] => 17/804979
[patent_app_country] => US
[patent_app_date] => 2022-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9298
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17804979
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/804979 | Albofungin and its derivatives specifically recognize HIV-1 LTR-III G-quadruplex | May 31, 2022 | Issued |
Array
(
[id] => 19104619
[patent_doc_number] => 11957692
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Clomipramine for the treatment of Alzheimer's Disease
[patent_app_type] => utility
[patent_app_number] => 17/751613
[patent_app_country] => US
[patent_app_date] => 2022-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 33
[patent_no_of_words] => 8813
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751613
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/751613 | Clomipramine for the treatment of Alzheimer's Disease | May 22, 2022 | Issued |
Array
(
[id] => 17851790
[patent_doc_number] => 20220281832
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => CRYSTAL MODIFICATIONS OF ODEVIXIBAT
[patent_app_type] => utility
[patent_app_number] => 17/744429
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744429
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/744429 | Crystal modifications of odevixibat | May 12, 2022 | Issued |
Array
(
[id] => 20179470
[patent_doc_number] => 20250263428
[patent_country] => US
[patent_kind] => A2
[patent_issue_date] => 2025-08-21
[patent_title] => AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/725689
[patent_app_country] => US
[patent_app_date] => 2022-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 228
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725689
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/725689 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF | Apr 20, 2022 | Pending |
Array
(
[id] => 20179470
[patent_doc_number] => 20250263428
[patent_country] => US
[patent_kind] => A2
[patent_issue_date] => 2025-08-21
[patent_title] => AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/725689
[patent_app_country] => US
[patent_app_date] => 2022-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 228
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725689
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/725689 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF | Apr 20, 2022 | Pending |
Array
(
[id] => 18964149
[patent_doc_number] => 11897899
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-13
[patent_title] => Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
[patent_app_type] => utility
[patent_app_number] => 17/726153
[patent_app_country] => US
[patent_app_date] => 2022-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 65546
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1253
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17726153
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/726153 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | Apr 20, 2022 | Issued |
Array
(
[id] => 18251474
[patent_doc_number] => 20230078513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/724753
[patent_app_country] => US
[patent_app_date] => 2022-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 153410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 574
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17724753
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/724753 | Inhibitors of plasma kallikrein and uses thereof | Apr 19, 2022 | Issued |
Array
(
[id] => 19225433
[patent_doc_number] => 12005063
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-11
[patent_title] => Medicament for preventing and/or treating dry eye
[patent_app_type] => utility
[patent_app_number] => 17/722947
[patent_app_country] => US
[patent_app_date] => 2022-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 5626
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722947
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/722947 | Medicament for preventing and/or treating dry eye | Apr 17, 2022 | Issued |
Array
(
[id] => 19472566
[patent_doc_number] => 12102628
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-01
[patent_title] => Composition and methods for the treatment of myopia
[patent_app_type] => utility
[patent_app_number] => 17/706225
[patent_app_country] => US
[patent_app_date] => 2022-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10851
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17706225
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/706225 | Composition and methods for the treatment of myopia | Mar 27, 2022 | Issued |
Array
(
[id] => 19403588
[patent_doc_number] => 20240287099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => 1,4-Sulfur-Bridged Polycyclic Compounds Containing Dihydrobenzofuran Structure, Its Preparation Method and Application Thereof
[patent_app_type] => utility
[patent_app_number] => 17/786470
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786470
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/786470 | 1,4-sulfur-bridged polycyclic compounds containing dihydrobenzofuran structure, its preparation method and application thereof | Mar 17, 2022 | Issued |
Array
(
[id] => 17720417
[patent_doc_number] => 20220213137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/694896
[patent_app_country] => US
[patent_app_date] => 2022-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54609
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17694896
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/694896 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | Mar 14, 2022 | Abandoned |
Array
(
[id] => 18102422
[patent_doc_number] => 11542297
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Compositions and methods for treating CNS disorders
[patent_app_type] => utility
[patent_app_number] => 17/695033
[patent_app_country] => US
[patent_app_date] => 2022-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54618
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17695033
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/695033 | Compositions and methods for treating CNS disorders | Mar 14, 2022 | Issued |
Array
(
[id] => 19871293
[patent_doc_number] => 12264137
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-01
[patent_title] => 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/691186
[patent_app_country] => US
[patent_app_date] => 2022-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18783
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 782
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691186
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/691186 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Mar 9, 2022 | Issued |
Array
(
[id] => 19012953
[patent_doc_number] => 11919868
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => Heterocyclic compounds and related methods
[patent_app_type] => utility
[patent_app_number] => 17/684352
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28453
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684352
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684352 | Heterocyclic compounds and related methods | Feb 28, 2022 | Issued |
Array
(
[id] => 18093055
[patent_doc_number] => 20220411396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => TRIOXOLANE AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/680825
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63872
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680825
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680825 | Trioxolane agents | Feb 24, 2022 | Issued |
Array
(
[id] => 19233711
[patent_doc_number] => 20240190903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/277204
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47750
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277204
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | Feb 24, 2022 | Pending |
Array
(
[id] => 19209862
[patent_doc_number] => 11998901
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Metal complex, method for producing same, and method for producing gamma-lactam compound using same
[patent_app_type] => utility
[patent_app_number] => 17/676078
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21071
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17676078
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/676078 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | Feb 17, 2022 | Issued |